The North Dakota Department of Health (NDDoH) encourages providers to be aware of acute flaccid myelitis (AFM) symptoms. Resources are provided in this Health Advisory to help with the identification and reporting of suspected AFM cases and specimen collection. AFM is an illness characterized by acute onset of flaccid limb weakness and magnetic resonance imaging (MRI) showing lesions in the gray matter of the spinal cord. AFM has been under investigation by the NDDoH and the Centers for Disease Control and Prevention (CDC) for the past four years. Surveillance has shown that AFM cases generally peak in the months of September and October. In the last four years, the majority of cases were reported in 2014 and 2016, and smaller numbers reported in 2015 and 2017 throughout the United States. If this pattern continues, an increase in AFM cases in 2018 may be expected. In October 2018 a cluster of AFM in children was identified in Minnesota. Other states have also reported AFM cases in 2018.

AFM appears to start with a prodromal respiratory or gastrointestinal illness about one week before limb weakness onset. Pain in the neck or back often directly precedes weakness in one or more limbs, and cranial nerve findings such as slurred speech, difficulty swallowing, and eyelid or facial droop may occur. On exam, the weak limb(s) displays poor tone and diminished reflexes. Cerebrospinal fluid may show a lymphocytic pleocytosis and elevated protein. MRI findings in AFM cases include lesions in the central, or gray matter, of the spinal cord. Because AFM is a relatively new condition, information on all patients is needed to help us better understand the spectrum of illness, and all possible causes, risk factors, and outcomes for AFM.

North Dakota Administrative Code 33-06-01 requires reporting of unexplained or emerging critical illnesses or deaths, which would include AFM. The NDDoH is requesting that all providers submit information about patients that meet the clinical criterion for AFM (sudden onset of flaccid limb weakness). Information should be sent on patients who meet the clinical criterion, regardless of laboratory results or MRI findings. There is no age restriction for reporting suspected cases. The case definition includes people of all ages to allow for full spectrum information of the condition in both children and adults. For more information about the case definition for AFM, please see www.cdc.gov/acute-flaccid-myelitis/hcp/case-definition.html.

Attached to this HAN is a Frequently Asked Questions (FAQs) about AFM and sample collection and shipping, and a clinician “job aid” to walk providers through the process of reporting a suspected AFM patient and sample collection, storage, and shipping. Call the NDDoH Division of Disease Control at 701.328.2378 with questions or email the CDC AFM team at limbweakness@cdc.gov.
To notify us of any patients who you are evaluating for acute onset of flaccid limb weakness, please call the Division of Disease Control at 701.328.2378.

Categories of Health Alert messages:

- **Health Alert** conveys the highest level of importance; warrants immediate action or attention.
- **Health Advisory** provides important information for a specific incident or situation; may not require immediate action.
- **Health Update** provides updated information regarding an incident or situation; no immediate action necessary.
- **Health Information** provides general information that is not necessarily considered to be of an emergent nature.

This message is being sent to local public health units, clinics, hospitals, physicians, tribal health, North Dakota Nurses Association, North Dakota Long Term Care Association, North Dakota Healthcare Association, North Dakota Medical Association, and hospital public information officers.
Job Aid for Clinicians
How to send information about a suspected AFM case to the health department

1. Identify suspected case of AFM: patient with onset of acute flaccid limb weakness

2. Contact your health department when you identify a suspected case of AFM.

Specimen Collection:
- Collect specimens as close to onset of limb weakness as possible and store as directed (see table on reverse side).
  - CSF
  - Serum
  - Stool
  - NP swab

AND

Information Sharing:
- Send copies of the following to your health department for sharing with CDC:
  - admission and discharge notes
  - neurology and infectious disease consult notes
  - MRI report
  - MRI images
  - vaccination history
  - laboratory test results

Send to:

Health Department
Contact:
North Dakota Department of Health Division of Microbiology at 701.328.6280 to arrange specimen shipment
And the Division of Disease Control at 701.328.2378 to arrange receipt of health records

Health department completes AFM Patient Summary Form, compiles medical records, and sends information to CDC. Patient will be classified by national AFM experts.

After expert review, patient classification is given back to health department and relayed to clinician by health department.
Specimens to collect and send to CDC for testing for suspected AFM cases

<table>
<thead>
<tr>
<th>SAMPLE</th>
<th>AMOUNT</th>
<th>TUBE TYPE</th>
<th>PROCESSING</th>
<th>STORAGE</th>
<th>SHIPPING</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSF</td>
<td>1mL (collect at same time or within 24hrs of serum)</td>
<td>Cryovial</td>
<td>Spun and CSF removed to cryovial</td>
<td>Freeze at -20°C</td>
<td>Ship on dry ice</td>
</tr>
<tr>
<td>Serum</td>
<td>≥0.4mL (collect at same time or within 24 hours of CSF)</td>
<td>Tiger/red top</td>
<td>Spun and serum removed to tiger/red top.</td>
<td>Freeze at -20°C</td>
<td>Ship on dry ice</td>
</tr>
<tr>
<td>Stool</td>
<td>≥1 gram (2 samples collected 24hrs apart)</td>
<td>Sterile container</td>
<td>n/a</td>
<td>Freeze at -20°C</td>
<td>Ship on dry ice. Rectal swabs should not be sent in place of stool.</td>
</tr>
<tr>
<td>Respiratory (NP)/Oropharyngeal (OP) swab</td>
<td>1ml (minimum amount)</td>
<td>n/a</td>
<td>Store in viral transport medium</td>
<td>Freeze at -20°C</td>
<td>Ship on dry ice</td>
</tr>
</tbody>
</table>

Coordinate with your health department to send information about suspected AFM cases and ship specimens to CDC.
Acute Flaccid Myelitis (AFM)
Frequently Asked Questions by Clinicians and Health Departments

Q: **What is a suspected case of AFM?**
A: A patient who presents with acute flaccid weakness of one or more limbs. No laboratory or MRI results are needed to alert public health officials about a case, and a diagnosis is not needed. The sooner the suspected case is reported, the likelihood of finding a cause is increased.

Q: **How do I report (alert the health authorities about) a suspected case of AFM?**
A: **Clinicians:** If you believe your patient has symptoms of AFM, such as acute flaccid weakness, contact your state or local health department as soon as possible for instructions on how to report. Urgent questions may also be directed to the CDC Emergency Operations Center (770-488-7100). Non-urgent questions can be emailed to the AFM team at limbweakness@cdc.gov. In addition, please collect biological specimens for testing as soon as possible to increase the possibility of finding a cause. These specimens can be tested at a hospital or state public health laboratory for enteroviruses, West Nile virus, and other infectious etiologies known to be associated with AFM. At the same time, additional aliquots of CSF, serum, stool, and respiratory samples should be sent to CDC for testing for both infectious and non-infectious causes. Additional instructions regarding CDC-specific specimen collection and shipping can be found on our Specimen Collection Instructions webpage at [www.cdc.gov/acute-flaccid-myelitis/hcp/instructions.html](http://www.cdc.gov/acute-flaccid-myelitis/hcp/instructions.html). For more information on how to send information about a suspected AFM case, see CDC’s [Job Aid for Clinicians](http://www.cdc.gov/acute-flaccid-myelitis/hcp/jobsaid.html).

Q: **Should I send information about a suspected case of AFM even if his/her clinical specimen was negative for enteroviruses?**
A: Yes, we encourage information about all suspected cases of AFM to be sent to the health department regardless of laboratory testing results. Although the outbreak of severe respiratory illness caused by enterovirus D68 (EV-D68) and the national cluster of AFM cases occurred around the same time in 2014, the pathogen or biologic mechanism responsible for AFM has not been identified yet. We request information and biological specimens from ANY patient suspected of having AFM (an illness with onset of acute flaccid limb weakness), regardless of whether they test positive or negative for an enterovirus.

Health departments: If you have received information about a suspected case of AFM, complete the [patient summary form](http://www.cdc.gov/acute-flaccid-myelitis/hcp/patientsummary.html) in conjunction with the clinician, collect the requested clinical information (i.e., admission and discharge notes, MRI report, MRI images, neurology consult notes, infectious disease consult notes, vaccination record, diagnostic laboratory results, and EMG report if done and available), and contact CDC (limbweakness@cdc.gov), to coordinate the case classification process.

For more information, visit: [www.cdc.gov/acute-flaccid-myelitis](http://www.cdc.gov/acute-flaccid-myelitis)

U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
National Center for Immunization and Respiratory Diseases (NCIRD)
Division of Viral Diseases

08/23/18
Q: **Should I send specimens to CDC even if the hospital laboratory or state public health laboratory can test for enteroviruses?**

A: Yes, we request that specimens (i.e., cerebrospinal fluid, serum, stool, and respiratory samples) be sent to CDC for standardized testing and for our expanded testing protocols. Contact your health department to coordinate sending of specimens to CDC for testing. Results from certain tests, such as enterovirus/rhinovirus testing and typing and stool testing, will be shared with specimen submitter and health department upon completion. The health department will then share the results with the clinician. For instructions on how to submit specimens to CDC, see our Specimen Collection Instructions webpage at www.cdc.gov/acute-flaccid-myelitis/hcp/instructions.html.

Q: **What happens to the patient specimens that I send to CDC, and when should I expect to receive the testing results?**

A: All specimens submitted to CDC help us learn more about AFM, including possible causes and how the immune system responds to this condition. Results from these tests should not be used to inform clinical management of your patient because results may not be available in real-time. Results from the respiratory testing for enterovirus/rhinovirus and typing and stool testing for poliovirus will be shared with the specimen submitter and health department as soon as they are completed. The health department will then share the results with the clinician. Results from other specimens (e.g., CSF and serum) will be used for exploratory testing to learn more about immune responses to AFM, and results will not be immediately available. Since CDC testing protocols include several immunoassays that are not approved by the Clinical Laboratory Improvement Amendments (CLIA) nor are intended for clinical diagnosis, CDC will be unable to provide patient-specific results for certain tests that are performed. However, results from exploratory testing of samples from multiple cases which may indicate a possible cause of AFM will be rapidly disseminated.

Q: **When should I expect AFM case classification results back from CDC?**

A: The process for case classification requires collection of many different pieces of information, including hospital notes and MRI images, which are then reviewed by several experts. Case classification is used for surveillance purposes and should not interfere with the differential or final clinical diagnosis or treatment of the patient. The case classification will be communicated through the state or local health department when the review is complete, generally about 4 weeks after all of the information is received.

Q: **Will CDC conduct extended follow-up on cases of AFM after their initial clinical presentation?**

A: Currently, we are working with health departments to collect short-term follow-up information (2 months after onset of limb weakness) about suspected cases of AFM. The health department may reach out to the treating clinician to collect this information. We conducted a short-term follow-up survey on cases with information collected during the 2014 investigation, and received responses from roughly half (56) of the identified cases. A small number described complete recovery of limb function after a median of about 4 months after onset of limb weakness. The majority described some improvement of function. A small number described no improvement in limb function. Information on long-term follow-up conducted on AFM cases from Colorado that occurred in 2014 can be found at www.neurology.org/content/89/2/129.

For more information on AFM, visit our For Clinicians and Health Departments webpage at www.cdc.gov/acute-flaccid-myelitis/hcp/index.html.